X @Bloomberg

UniQure’s shares plunged after US regulators said the company should conduct another study of its gene therapy for Huntington’s disease before it’s approved, the most recent example of the Trump administration slowing treatment for a rare disease https://t.co/o8lUDhxlmD ...